Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 118, Issue 6, pp 1311–1314 | Cite as

Circulating serum interferon andits effect on the activity of human natural killer cells

  • S. B. Cheknev
  • Ya. G. Ashmanova
  • A. D. Pritsker
  • O. L. Latysheva
Microbiology and Immunology
  • 12 Downloads

Abstract

The interferon content in the plasma of 6 healthy donors and 10 patients with multiple sclerosis and the effect of an 1-h treatment of mononuclear cells with autologous plasma on their natural killer activity are studiedin vitro using3H-uridine-labeled (3 μCi/ml) human erythromyeloleukosis cells K-562. The serum interferon content in healthy donors is 2.3±0.82 IU/ml, whereas that in patients is higher: 5.2±0.8 IU/ml. Autologous plasma does not affect the activity of natural killer cellsin vitro, whereas it increases the cytotoxicity of mononuclear cells obtained from patients with multiple sclerosis by 35–64%.

Key Words

circulating interferon natural killer activity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    V. P. Kuznetsov,Immunologiya, No 4, 30–34 (1987).Google Scholar
  2. 2.
    V. D. Solov'ev and T. A. Bektimirov,Vestn. Akad. Med. Nauk SSSR, No 2, 19–26 (1979).PubMedGoogle Scholar
  3. 3.
    A. M. Sorokin, S. B. Cheknev, and V. P. Kuznetsov,Immunologiya, No 1, 17–20 (1991).Google Scholar
  4. 4.
    M. P. Rykova, I. V. Spirande, M. S. Zedgenidze,et al.,, No 3, 88–90 (1981).Google Scholar
  5. 5.
    S. B. Cheknev,, No 6, 8–12 (1993).Google Scholar
  6. 6.
    S. B. Cheknev, M. Z. Saidov, L. V. Koval'chuk,et al., Lab. Delo., No 3, 231–234 (1987).PubMedGoogle Scholar
  7. 7.
    S. B. Cheknev, O. L. Latysheva, I. S. Frolova,et al., in:Inteferon-89, Moscow (1989), pp. 42–47.Google Scholar
  8. 8.
    S. B. Cheknev, A. M. Sorokin, and L. V. Koval'chuk,Immunologiya, No 3, 48–52 (1989).Google Scholar
  9. 9.
    L. Ya. Babynina, Z. V. Volobueva, and V. M. Ermekova,Europ. Fed. Immunol. Soc. 10th Meet., Edinburgh (1990), p. 65.Google Scholar
  10. 10.
    V. Bocci,Immunology Today,6, No 1, 7–9 (1985).CrossRefGoogle Scholar
  11. 11.
    V. Bocci,Immunology,64, 1–9 (1988).PubMedGoogle Scholar
  12. 12.
    S. B. Cheknev, in:Advances in Modern Biotechnology, Vol. 1, Havana (1992), p. 20.7.Google Scholar
  13. 13.
    W. R. Fleishmann Jr., J. A. Georgiades, L. C. Osborne,et al., Infect. Immunol.,26, 949–955 (1979).Google Scholar
  14. 14.
    K. Frei, S. Fredrikson, A. Fontana, and H. Link,J. Neuroimmunol.,31, No 2, 147–153 (1991).PubMedCrossRefGoogle Scholar
  15. 15.
    R. M. Friedman and S. N. Vogel, in:Advances in Immunology, Eds. F. J. Dixo and H. G. Kunkel, Vol. 34, New York (1983), pp. 97–140.Google Scholar
  16. 16.
    K. P. Hammann and H. C. Hopf,J. Neuroimmunol,13, No 1, 9–18 (1986).PubMedCrossRefGoogle Scholar
  17. 17.
    R. B. Herberman and J. R. Ortaldo,Science,214, 24–30 (1981).PubMedGoogle Scholar
  18. 18.
    E. Kott, T. Hahn, M. Huberman,et al., Quart. J. Med.,76, No 281, 951–960 (1990).PubMedGoogle Scholar
  19. 19.
    S. Krown, F. X. Real, S. Vadhan-Raj, and H. F. Oettgen,J. Exp. Pathol.,3, No 4, 681–691 (1987).PubMedGoogle Scholar
  20. 20.
    O. T. Preble, R. J. Black, R. M. Friedman,et al., Science,216, 429–431 (1982).PubMedGoogle Scholar
  21. 21.
    A. Rhodes-Feuillette, M. Canivet, H. Champsaur,et al., J. Interferon Res.,3, No 1, 45–52 (1983).PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1995

Authors and Affiliations

  • S. B. Cheknev
    • 1
    • 2
  • Ya. G. Ashmanova
    • 1
    • 2
  • A. D. Pritsker
    • 1
    • 2
  • O. L. Latysheva
    • 1
    • 2
  1. 1.Laboratory of Immunochemistry, Department of Interferons, N. F. Gamaleya Institute of Epidemiology and MicrobiologyRussian Academy of Medical SciencesMoscow
  2. 2.Department of NeurologyN. I. Pirogov Municipal Hospital No. 1Moscow

Personalised recommendations